Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Depreciation & Amortization (IS)Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Ocular Therapeutix (OCUL) Shares Issued (2016 - 2026)

Ocular Therapeutix has reported Shares Issued over the past 14 years, most recently at $294000.0 for Q1 2026.

For Q1 2026, Shares Issued fell 92.97% year-over-year to $294000.0; the TTM value through Mar 2026 reached $710.3 million, up 328.29%, while the annual FY2025 figure was $539.6 million, 53008.76% up from the prior year.
Shares Issued for Q1 2026 was $294000.0 at Ocular Therapeutix, down from $522.0 million in the prior quarter.
Over five years, Shares Issued peaked at $522.0 million in Q4 2025 and troughed at -$309.8 million in Q2 2024.
A 5-year average of $45.4 million and a median of $438500.0 in 2022 define the central range for Shares Issued.
On a YoY basis, Shares Issued climbed as much as 405480.77% in 2024 and fell as far as 3610.64% in 2024.
Year by year, Shares Issued stood at $32000.0 in 2022, then plummeted by 75.0% to $8000.0 in 2023, then surged by 6450.0% to $524000.0 in 2024, then soared by 99514.12% to $522.0 million in 2025, then plummeted by 99.94% to $294000.0 in 2026.
Business Quant data shows Shares Issued for OCUL at $294000.0 in Q1 2026, $522.0 million in Q4 2025, and $94.0 million in Q3 2025.